Alfuzosin Hydrochloride Tablet, Extended Release
Product Images NDC 72162-1449

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Alfuzosin Hydrochloride (NDC 72162-1449). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Chemical-structure (Chemical Structure)

Chemical-structure (Chemical Structure)
FDA Label Image

Figure-1 (Figure 1)

Figure-1 (Figure 1)
FDA Label Image

Figure-2 (Figure 2)

Figure-2 (Figure 2)
This text provides data comparing the efficacy of Alfuzosin hydrochloride extended-release tablets with a placebo in a clinical trial. The information includes the number of participants in each group (N=167 for placebo and N=170 for Alfuzosin), the timeline of treatment (0, 28, 56, 84 days), and a statistically significant result (***p< 0.001) for the mean change from baseline in IPSS Total Symptom Score during Trial 1.*
FDA Label Image

Figure-3 (Figure 3)

Figure-3 (Figure 3)
Mean change in IPSS Total Symptom Score is compared between Placebo (N=152) and Alfuzosin hydrochloride extended-release tablets (N=137) after 28 and 56 days of treatment in Trial 2. The statistical significance is indicated as **p < 0.01.*
FDA Label Image

Figure-4 (Figure 4)

Figure-4 (Figure 4)
This document provides data on the mean change from the baseline in the International Prostate Symptom Score (IPSS) Total Symptom Score over a 28 to 56 days treatment period. The study compared the effects of a placebo group of 150 individuals with a group taking Alfuzosin hydrochloride extended-release tablets consisting of 151 individuals. The results show a statistically significant difference with a p-value of less than 0.01. This information is likely part of Trial 3 of a clinical trial or study.*
FDA Label Image

Figure-5 (Figure 5)

Figure-5 (Figure 5)
This text provides information on mean change from baseline in peak urine flow rate (mL/s) over 56 days of treatment with placebo and alfuzosin hydrochloride extended-release tablets. The study included 167 patients in the placebo group and 170 patients in the alfuzosin group, showing a significant difference in peak urine flow rate.*
FDA Label Image

Figure-6 (Figure 6)

Figure-6 (Figure 6)
FDA Label Image

Figure-7 (Figure 7)

Figure-7 (Figure 7)
This is a comparison of the mean change from baseline in peak urine flow rate for a trial involving Placebo (N=150) and Alfuzosin hydrochloride extended-release tablets (N=151) over 84 days of treatment. The data shows that there was no significant difference between the two groups (p > 0.05).*
FDA Label Image

Label (Lbl721621449)

Label (Lbl721621449)
This is a description of Alfuzosin Hydrochloride extended-release tablets containing 10 mg per tablet. The medication is stored in temperatures between 15° to 30°C. It is recommended to dispense in a tight, light-resistant container, protect from light and moisture, and keep out of reach of children. The usual dosage and other important information can be found in the package insert available at a specific website. The tablets should be swallowed whole and not chewed or crushed.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.